NeuroSense to Discuss PrimeC ALS Strategy in Upcoming Roth Webinar

The virtual event, titled "A Quest to Outrun Amyotrophic Lateral Sclerosis," features a conversation between NeuroSense CEO Alon Ben-Noon and Professor Jeremy Shefner, Chair of Neurology at Barrow Neurological Institute. Moderated by Roth Capital Partners analyst Boobalan Pachaiyappan, the discussion aims to address the persistent hurdles in ALS drug development and the refinement of clinical trial endpoints to better capture disease progression.

Central to the dialogue is the role of PrimeC, an oral therapy currently moving toward a pivotal Phase 3 PARAGON study. The company intends to highlight how this candidate, which targets neuroinflammation and oxidative stress, differentiates itself from existing standards of care. The webinar will also explore the potential for FDA accelerated approval and the long-term commercial outlook for the treatment in an evolving market.